Corporate ActionJul 29, 2026, 04:08 PM
Attovia Therapeutics Files for IPO, Offering 12.5M Shares at $15-17
AI Summary
Attovia Therapeutics, Inc. filed an S-1/A for its initial public offering, proposing to sell 12,500,000 shares of common stock at an estimated price range of $15.00 to $17.00 per share. The company expects to raise approximately $182.4 million in net proceeds, which will be used to advance its clinical pipeline, including ATTO-1310, ATTO-2306, and ATTO-1091, as well as for general corporate purposes. The company also reported a preliminary cash balance of $115.1 million as of June 30, 2026.
Key Highlights
- Proposing an IPO of 12,500,000 common shares.
- Estimated IPO price range is $15.00 to $17.00 per share.
- Expected net proceeds of approximately $182.4 million.
- Proceeds to fund clinical development of ATTO-1310, ATTO-2306, and ATTO-1091.
- Preliminary cash, cash equivalents, and marketable securities of $115.1 million as of June 30, 2026.
- ATTO-1310 completed Phase 1 clinical trial in Q1 2026.
- ATTO-2306 and ATTO-1091 Phase 1 trials expected in H1 2027.
- Effected a 1-for-9.29 reverse stock split on July 29, 2026.
Price Impact
More from ATTO